Proceedings of the 2nd Global Health and Innovation in conjunction with 6th ORL Head and Neck Oncology Conference (ORLHN 2021)

<Previous Article In Volume
Next Article In Volume>

Pembrolizumab Efficacy in Treatment of Carcinoma of the Head and Neck Squamous Cell

Authors
Yussy Afriani Dewi*, Ifiq Budiyan Nazar, Betty S. Hermono
Depart of Otorhinolaryngology-Head and Neck Surgery, Faculty of Medicine Universitas Padjadjaran/Hasan Sadikin General Hospital, Indonesia
*Corresponding author. Email: yussy.afriani@unpad.ac.id
Corresponding Author
Yussy Afriani Dewi
Available Online 21 February 2022.
DOI
10.2991/ahsr.k.220206.019How to use a DOI?
Keywords
Cancer Treatment; Head and Neck Squamous Cell Carcinoma; Immunotherapy; Pembrolizumab
Abstract

Immunotherapy acts by a system of immune modulation to destruct cells of cancer. Squamous cell carcinoma of the head and neck (HNSCC), this modality can be administered alone or combined with other therapies. Currently, immunotherapy with chemotherapy has shown better effectiveness as first-line systemic therapy. Immunotherapy drugs are divided into T-cell treatment and checkpoint inhibitors divided into chimeric antigen receptor (CAR). Pembrolizumab is categorized as checkpoint inhibitors and is currently being researched for its role in HNSCCs management. Pembrolizumab can be used the first or second-line for recurrent or metastatic (R/M) HNSCC. In addition, the side effects of Pembrolizumab are more tolerable than standard chemotherapy regimens.

Copyright
© 2022 The Authors. Published by Atlantis Press International B.V.
Open Access
This is an open access article under the CC BY-NC license.

Download article (PDF)

<Previous Article In Volume
Next Article In Volume>
Volume Title
Proceedings of the 2nd Global Health and Innovation in conjunction with 6th ORL Head and Neck Oncology Conference (ORLHN 2021)
Series
Advances in Health Sciences Research
Publication Date
21 February 2022
ISBN
10.2991/ahsr.k.220206.019
ISSN
2468-5739
DOI
10.2991/ahsr.k.220206.019How to use a DOI?
Copyright
© 2022 The Authors. Published by Atlantis Press International B.V.
Open Access
This is an open access article under the CC BY-NC license.

Cite this article

risenwbib
TY  - CONF
AU  - Yussy Afriani Dewi
AU  - Ifiq Budiyan Nazar
AU  - Betty S. Hermono
PY  - 2022
DA  - 2022/02/21
TI  - Pembrolizumab Efficacy in Treatment of Carcinoma of the Head and Neck Squamous Cell
BT  - Proceedings of the 2nd Global Health and Innovation in conjunction with 6th ORL Head and Neck Oncology Conference (ORLHN 2021)
PB  - Atlantis Press
SP  - 93
EP  - 96
SN  - 2468-5739
UR  - https://doi.org/10.2991/ahsr.k.220206.019
DO  - 10.2991/ahsr.k.220206.019
ID  - Dewi2022
ER  -